NO20061598L - Sulfonamidderivater til behandling av diabetes - Google Patents
Sulfonamidderivater til behandling av diabetesInfo
- Publication number
- NO20061598L NO20061598L NO20061598A NO20061598A NO20061598L NO 20061598 L NO20061598 L NO 20061598L NO 20061598 A NO20061598 A NO 20061598A NO 20061598 A NO20061598 A NO 20061598A NO 20061598 L NO20061598 L NO 20061598L
- Authority
- NO
- Norway
- Prior art keywords
- group
- sulfonamide
- treatment
- hydrogen
- nitrogen atom
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 3
- 150000003456 sulfonamides Chemical class 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- -1 amino, sulfanyl Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000003863 ammonium salts Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Foreliggende oppfinnelse angår anvendelse av sulfonamidderivater for behandling av metabolske lidelser kontrollert eller forårsaket av insulinresistens eller hyperglykemi, og som omfatter diabetes type II, utilstrekkelig glukosetoleranse, insulinresistens, overvekt og polycystisk eggstokksyndrom (PCOS). Formel (I). R1 er valgt fra gruppen bestående av hydrogen, C1-C6-alkoksy, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, amino, sulfanyl, sulfinyl, sulfonyl, sulfonyloksy, sulfonamid, acylamino, aminokarbonyl, C1-C6-alkoksykarbonyl, aryl, heteroaryl, karboksy, cyano, halogen, hydroksy, nitro, hydrazider. R2 er valgt fra gruppen bestående av hydrogen, COOR3, -CONR3R3', OH, en C1-C4-alkyl substituert med en OH-eller aminogruppe, en hydrazidokarbonylgruppe, et sulfat, et sulfonat, et amin eller et ammoniumsalt. Y er en 4-12 leddet mettet syklisk eller bisyklisk alkylgruppe som inneholder minst ett nitrogenatom, og hvor ett nitrogenatom i nevnte ring danner en binding med sulfonylgruppen med formel I, og således tilveiebringer sulfonamidet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102742 | 2003-09-12 | ||
| PCT/EP2004/052143 WO2005025558A1 (en) | 2003-09-12 | 2004-09-13 | Sulfonamide derivatives for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061598L true NO20061598L (no) | 2006-06-09 |
Family
ID=34306923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061598A NO20061598L (no) | 2003-09-12 | 2006-04-07 | Sulfonamidderivater til behandling av diabetes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7705052B2 (no) |
| EP (1) | EP1663193B1 (no) |
| JP (1) | JP4870562B2 (no) |
| AT (1) | ATE551997T1 (no) |
| AU (1) | AU2004271741A1 (no) |
| CA (1) | CA2534312A1 (no) |
| ES (1) | ES2385219T3 (no) |
| IL (1) | IL174251A0 (no) |
| NO (1) | NO20061598L (no) |
| WO (1) | WO2005025558A1 (no) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159767A0 (en) * | 2001-07-23 | 2004-06-20 | Applied Research Systems | Sulfonamide derivatives, their preparation and pharmacetuical compositions containing them |
| ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
| AU2011265521B8 (en) * | 2005-07-15 | 2014-05-22 | Merck Serono Sa | JNK inhibitors for the treatment of endometreosis |
| EP1919896B1 (en) * | 2005-08-12 | 2009-12-23 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands. |
| PL2106260T3 (pl) | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
| US8225729B2 (en) * | 2008-12-16 | 2012-07-24 | Kimberly-Clark Worldwide, Inc. | Three-dimensional wiping substrate and method therefor |
| US8882735B2 (en) * | 2008-12-16 | 2014-11-11 | Kimberly-Clark Worldwide, Inc. | Article with fluid-activated barriers |
| US8507746B2 (en) * | 2008-12-16 | 2013-08-13 | Kimberly-Clark Worldwide, Inc. | Leakage-signaling absorbent article |
| US7858055B2 (en) * | 2008-12-18 | 2010-12-28 | Kimberly-Clark Worldwide, Inc. | Moisture sensitive auxetic material |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| RU2599248C2 (ru) | 2010-04-19 | 2016-10-10 | Оризон Дженомикс С.А. | Лизинспецифические ингибиторы деметилазы-1 и их применение |
| SG186885A1 (en) | 2010-06-04 | 2013-02-28 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| ME03085B (me) | 2010-07-29 | 2019-01-20 | Oryzon Genomics Sa | Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena |
| WO2012027261A1 (en) * | 2010-08-23 | 2012-03-01 | Amgen Inc. | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| US8708988B2 (en) | 2010-12-03 | 2014-04-29 | Kimberly-Clark Worldwide, Inc. | Absorbent article configured for controlled deformation |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| BR112014009306B1 (pt) * | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
| BR112014009238B1 (pt) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas |
| WO2014156196A1 (ja) * | 2013-03-29 | 2014-10-02 | 一般社団法人ファルマバレープロジェクト支援機構 | ２型糖尿病治療剤 |
| PT3105226T (pt) | 2014-02-13 | 2019-11-06 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| ME03654B (me) * | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EA039196B1 (ru) * | 2014-10-08 | 2021-12-16 | Инсайт Корпорейшн | Циклопропиламины в качестве ингибиторов lsd1 |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
| JP6920411B2 (ja) * | 2016-07-25 | 2021-08-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN119462614B (zh) * | 2025-01-14 | 2025-05-02 | 吉林大学 | 1-mhmd、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
| US4927831A (en) | 1988-10-20 | 1990-05-22 | American Home Products | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors |
| HU228111B1 (en) | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
| EP1088815A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
| EP1193267A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases |
| EP1193256A1 (en) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins |
| EP1193268A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| US20020198203A1 (en) | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and a thiazolidinedione agent |
| IL159767A0 (en) * | 2001-07-23 | 2004-06-20 | Applied Research Systems | Sulfonamide derivatives, their preparation and pharmacetuical compositions containing them |
| ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
-
2004
- 2004-09-13 AT AT04787131T patent/ATE551997T1/de active
- 2004-09-13 ES ES04787131T patent/ES2385219T3/es not_active Expired - Lifetime
- 2004-09-13 CA CA002534312A patent/CA2534312A1/en not_active Abandoned
- 2004-09-13 US US10/571,466 patent/US7705052B2/en not_active Expired - Fee Related
- 2004-09-13 EP EP04787131A patent/EP1663193B1/en not_active Expired - Lifetime
- 2004-09-13 JP JP2006525836A patent/JP4870562B2/ja not_active Expired - Fee Related
- 2004-09-13 WO PCT/EP2004/052143 patent/WO2005025558A1/en not_active Ceased
- 2004-09-13 AU AU2004271741A patent/AU2004271741A1/en not_active Abandoned
-
2006
- 2006-03-12 IL IL174251A patent/IL174251A0/en unknown
- 2006-04-07 NO NO20061598A patent/NO20061598L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005025558A1 (en) | 2005-03-24 |
| ATE551997T1 (de) | 2012-04-15 |
| JP4870562B2 (ja) | 2012-02-08 |
| ES2385219T3 (es) | 2012-07-19 |
| CA2534312A1 (en) | 2005-03-24 |
| IL174251A0 (en) | 2006-08-01 |
| US7705052B2 (en) | 2010-04-27 |
| US20070043027A1 (en) | 2007-02-22 |
| AU2004271741A1 (en) | 2005-03-24 |
| EP1663193B1 (en) | 2012-04-04 |
| EP1663193A1 (en) | 2006-06-07 |
| JP2007505088A (ja) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061598L (no) | Sulfonamidderivater til behandling av diabetes | |
| ES2572155T3 (es) | Compuestos insecticidas | |
| EP1873144A4 (en) | CONDENSED HETEROCYCLIC COMPOUND | |
| NO20083480L (no) | Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister | |
| PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
| ATE472531T1 (de) | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
| EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| WO2009063910A1 (ja) | 光学活性イソキサゾリン化合物の触媒的不斉合成方法 | |
| ATE523507T1 (de) | Piperidin-gpcr-agonisten | |
| WO2008155668A3 (en) | Heteroarylamide pyrimidone compounds | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| NO20072382L (no) | (S)-(-)-1-(4-Fluorisokinolin-5-yl)-sulfonyl-2-metyl-1,4-homopiperazinhydroklorid dihydrat | |
| MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| WO2008155669A3 (en) | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| ATE455772T1 (de) | Alkinylarylcarbonsäureamide | |
| ATE431333T1 (de) | Amino-propanolderivate | |
| NO20061614L (no) | Benzimidazolacetonitriler | |
| UA86836C2 (ru) | Производные изоксазолина, способ их получения (варианты), гербицидная композиция и способ угнетения роста сорняков | |
| CY1113042T1 (el) | Αντιμετωπιση μυϊασης | |
| DK1907396T3 (da) | Fremgangsmåde til fremstilling af 4-beta-amino-4'-demethyl-4-deoxypodophyllotoxin | |
| DE602004024170D1 (de) | Pyrrolidin-derivate als oxytocin antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |